Toshiba Showcases End-to-End Innovations Shaping What’s Next in Retail at EuroShop 2026 February 23, 2026 At EuroShop, Toshiba showcases intelligent, scalable solutions that combine AI, computer vision, and energy-efficient design to transform the future of retail.
Graphene Launches Authorised Investment Platform for Alpha Investment Office February 23, 2026 Platform delivers regulated infrastructure, custody connectivity and end-to-end investment operations to support Alpha’s growth strategy
Almirall’s 2025 Results February 23, 2026 Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory. This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM). The continued strong performance of the biologics portfolio is the backbone of Almirall’s growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after launch. Continued solid performance of the broad dermatology product portfolio with Wynzora® growing 30.5% YoY to a total of €33.8 MM, and Klisyri® growing 33.9% YoY to a total of €32.8 MM, further enhances Almirall’s position as trusted partner for patients and dermatologists. Almirall’s business performance fuels the advancement of a diversified and innovative R&D pipeline addressing skin diseases with high unmet need. Pipeline progress in 2025 included the start of the phase II study of the anti-IL-1RAP mAb in Hidradenitis suppurativa, the start of the phase II study of the IL-2muFc in Alopecia areata, and the approval of Jublia® in Germany and Seysara® in China. Guidance for 2026: net sales growth of 9%-12% and total EBITDA between €270 MM and €290 MM.
AHS Tower Fully Sold During Development, Generating More Than USD 700 Million February 23, 2026 A new commercial landmark on Sheikh Zayed Road underscores market momentum for next-generation workspaces in Dubai.
INCERGO S.A. Announces Share Capital Increase and Strategic Shareholding with Visual Semiconductor February 23, 2026 INCERGO S.A. (Symbol: ICG) announces that, effective February 19, 2026, its issued share capital has increased from 5,060,000 to 151,283,387 registered ordinary shares. The issuance of 146,223,387 new shares has been duly registered and is effective on the Vienna Stock Exchange as of today. The company announced further progress in its merger with Visual Semiconductor [...]
Capitolis to Acquire 20 Gates Management’s U.S. Secured Financing Platform to Expand its Capital Marketplace February 20, 2026 Strategic acquisition enables Capitolis to deliver U.S. secured financing through its Capital Marketplace, broadens client base, and adds veteran industry talent
Telekom Srbija Group Announces Platinum Sponsorship of EXPO 2027 Belgrade February 20, 2026 Telekom Srbija to power EXPO 2027 and unveil dedicated pavilion showcasing its technology ecosystem
Cloudflare and Mastercard Partner to Extend Comprehensive Cyber Defense Across Critical Infrastructure and Small Businesses February 17, 2026 Combined security offerings will uncover hidden risks, assess security posture, and automate defenses for all web-facing assets
North Highland Welcomes Nyla Beth Gawel as Senior Managing Director February 17, 2026 Gawel's appointment strengthens the firm's workforce strategy expertise
Corpay Cross-Border Named the Official Commercial FX Partner of Prima Pramac Racing February 17, 2026 Providing access to currency risk management and cross-border payments solutions
